The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis

Chinese PLA General Hospital1 site in 1 country230 target enrollmentOctober 2016

ConditionsLung Neoplasm Lung Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Lung Neoplasm
Sponsor: Chinese PLA General Hospital
Enrollment: 230
Locations: 1
Primary Endpoint: Mass-to-charge Ratio
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to analysis the volatile organic gases(VOCs) in exhaled breath of pulmonary lesion patients and healthy controls, in order to find the difference of composition and concentration among groups.

Detailed Description

Collect the exhaled gas in pulmonary lesion patients and healthy controls, using proton transfer reaction mass spectrometry to analysis the different composition and concentration of VOCs, to find the biomarker gases of distinguishing benign and malignant lesion of lung among different groups， and try to build a diagnostic model for lung lesion.

Registry

clinicaltrials.gov

Start Date

October 2016

End Date

August 2017

Last Updated

9 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Chinese PLA General Hospital

Responsible Party

Principal Investigator

Chen Liang_An

MD,PHD

Chinese PLA General Hospital

Eligibility Criteria

Inclusion Criteria

•cohort 1 :
•Inclusion criteria:
•Patients newly diagnosed with primary lung cancer by tissue biopsy and did not receive any treatment aiming at the tumor, including chemotherapy and radiotherapy.
•Age ≥ 18 years
•cohort 2： Inclusion criteria： Patients diagnosed with pulmonary benign lesion by tissue biopsy or other examination.
•Age ≥ 18 years

Exclusion Criteria

•patients who have more than one type of carcinoma patients diagnosed type 2 diabetes mellitus patients diagnosed chronic renal failure patients diagnosed upper digestive tract ulcer patients who reject to sign the informed consent from
•cohort 3： Healthy controls Volunteers without diagnosed lung diseases and pulmonary symptoms.